CureVac: Dispute over vaccine company reaches circle of G7 countries - Merkel: CureVac issue is 'solved' - News-Credit-Mortgage-Coin

Breaking

Car donation, Insurance, Credit, Money, news

Coin Market

Monday, March 16, 2020

CureVac: Dispute over vaccine company reaches circle of G7 countries - Merkel: CureVac issue is 'solved'

Chancellor Angela Merkel (CDU) considers the dispute with the United States over the Tübingen vaccine company CureVac to be over.
"The latter did not play a role today, especially since the issue has also been solved, as we could say at the weekend," said Merkel on Monday in Berlin. The federal government "took care of it very early on". The Chancellor also referred to statements by the entrepreneur Dietmar Hopp and the top management that an exclusive contract with the United States, for example, for a Corona vaccine for CureVac was out of the question.

The European Commission wants to support CureVac with up to 80 million euros in the development of an anti-coronavirus agent. "The EU supported their research at an early stage and will now help again financially," said Commission President Ursula von der Leyen in Brussels after she and Research Commissioner Mariya Gabriel had called CureVac. The aim is to find a vaccine "that helps the whole world" as soon as possible.



There had been reports over the weekend that the United States wanted to acquire exclusive rights to a CureVac coronavirus vaccine.

The alleged attempt by the US government had also concerned the G7 group. He had already spoken to his colleagues from Canada, South Korea, Brazil and Australia about this, Foreign Minister Heiko Maas (SPD) told the newspapers of the Funke media group (Monday). "German researchers are leaders in the development of drugs and vaccines, in global collaborations. We cannot allow others to exclusively acquire their research results." A CureVac spokesman said on Monday: "We have no offer."

The biotech company informed the "Schwäbische Zeitung" (Monday) that an acquisition by an American company or by the USA was not in the room. There is certainly interest from the USA in the work of CureVac, but "Corona is a worldwide problem, we work for it," said Franz-Werner Haas, the executive board member responsible for production at CureVac. CureVac has been researching a vaccine against the coronavirus since January.
The Federal Ministry of Economics affirmed the fundamental importance of free access to a possible vaccine against the coronavirus. "The Federal Government is very interested that we produce active ingredients and vaccines in Germany and Europe," said a spokeswoman for the ministry on Monday in Berlin.

First, the "Welt am Sonntag" reported on disputes about CureVac. US President Donald Trump is trying to lure German scientists to America with high financial donations or to secure the drug exclusively for his country, the newspaper reported, citing government circles in Berlin.
A senior government official did not confirm the newspaper report on Sunday evening (local time). On request, he said that neither the report of the "Welt am Sonntag" nor the underlying information is known. The US ambassador in Berlin, Richard Grenell, described the report on Twitter as untrue.
According to a report by the newspaper "Mannheimer Morgen" on Sunday, the managing director and co-founder of the main investor dievini Hopp BioTech Holding, Christof Hettich, made it clear that an exclusive contract, for example with the USA, for a corona vaccine for CureVac was out of the question. According to the report, the SAP (SAP SE) co-founder and patron Hopp and the entrepreneur Friedrich von Bohlen are among the founders and managing directors of the company.
CureVac is currently researching a vaccine against the corona virus and has received 8.3 million US dollars in funding from the international vaccine alliance CEPI ("Coalition for Epidemic Preparedness Innovations"). The federal government is also a member of CEPI./cn/DP/he

No comments:

Post a Comment